Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
Top Cited Papers
- 2 June 2009
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 373 (9679), 1949-1957
- https://doi.org/10.1016/s0140-6736(09)60691-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV InfectionThe Journal of Infectious Diseases, 2007
- Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young womenInfectious Agents and Cancer, 2007
- Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysisThe Lancet Infectious Diseases, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsNew England Journal of Medicine, 2007
- Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineVaccine, 2007
- Chapter 1: HPV in the etiology of human cancerVaccine, 2006
- Incidence, Duration, and Determinants of Cervical Human Papillomavirus Infection in a Cohort of Colombian Women with Normal Cytological ResultsThe Journal of Infectious Diseases, 2004
- The 2001 Bethesda SystemTerminology for Reporting Results of Cervical CytologyJAMA, 2002
- High incidence of cervical human papillomavirus infection in women during their first sexual relationshipBJOG: An International Journal of Obstetrics and Gynaecology, 2002